title: Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
abstract: This 8-week, open-label extension of a double-blind study reports on safety data for 171 adolescents with attention-deficit/hyperactivity disorder (ADHD) who received once-daily OROS methylphenidate (MPH) (18-72 mg/day). Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events. The incidence of adverse events was not related to dose. OROS MPH was safe and well tolerated at doses up to 72 mg/day.
authors.affiliation: Semel Institute for Neuroscience and Human Behavior, and David Geffen School of Medicine at UCLA, 300 UCLA Medical Plaza, Los Angeles, CA 90095, USA. jmcgough@mednet.ucla.edu
authors.forename: James J
authors.initials: JJ
authors.lastname: McGough
authors.forename: Keith
authors.initials: K
authors.lastname: McBurnett
authors.forename: Oscar
authors.initials: O
authors.lastname: Bukstein
authors.forename: Timothy E
authors.initials: TE
authors.lastname: Wilens
authors.forename: Laurence
authors.initials: L
authors.lastname: Greenhill
authors.forename: Marc
authors.initials: M
authors.lastname: Lerner
authors.forename: Mark
authors.initials: M
authors.lastname: Stein
mesh_terms: D000293:Adolescent; D000855:Anorexia / Q000139:chemically induced; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D015431:Weight Loss
chemical_list: D000697:Central Nervous System Stimulants; D008774:Methylphenidate